sh-Polypeptide-71 for Hair Regrowth
Evidence Review created on 11/12/2026 using AI4L + evidence-mcp / Opus 5.5
Also known as: sh-Polypeptide-65, Recombinant Human Vasoactive Intestinal Peptide, rh-VIP, Vasoactive Intestinal Peptide, VIP, Clairesome-VP
Motivation
sh-Polypeptide-71 is a lab-made copy of vasoactive intestinal peptide, a small signaling protein that nerve endings release around hair follicles. It appears in scalp serums, shampoos and lash products marketed for thicker hair. Interest rests on one idea: the peptide is thought to widen tiny blood vessels and to help keep the immune system from attacking hair follicles.
The ingredient belongs to a family of lab-made human signaling proteins sold as cosmetics under standardized ingredient names. It drew attention for hair when a group of plastic surgeons included it in a solution of several lab-made proteins that patients pressed into the scalp with a needle stamp combined with red light, in people with pattern hair loss and in people shedding hair after a coronavirus infection.
This review examines what is known about sh-Polypeptide-71 for regrowing scalp hair: how it is proposed to work, what the human data actually tested, its potential harms, how it is used in practice and how strong the evidence is for adults who are prepared to follow demanding hair-care routines.
Benefits - Risks - Protocol - Conclusion
Recommended Reading
The items below discuss sh-Polypeptide-71, its parent molecule vasoactive intestinal peptide (VIP, a nerve-derived signaling peptide), or the growth-factor and microneedling approach through which it has been tested on the scalp.
-
The Science of Healthy Hair, Hair Loss and How to Regrow Hair - Andrew Huberman
Covers increasing blood flow to follicle stem cells, platelet-rich plasma and microneedling, the same vessel-widening mechanism and needle-assisted delivery through which sh-Polypeptide-71 has been tested.
-
Vasoactive intestinal peptide, whose receptor-mediated signalling may be defective in alopecia areata, provides protection from hair follicle immune privilege collapse. - Bertolini et al., 2016
Primary study showing that human scalp follicles carry VIP receptors and that VIP protects cultured follicles’ immune privilege (shelter from immune attack), whose loss drives alopecia areata (autoimmune patchy hair loss).
-
Preliminary Investigation on Micro-Needling with Low-Level LED Therapy and Growth Factors in Hair Loss Related to COVID-19. - Gentile, 2022
Case series in shedding after COVID-19 (coronavirus disease 2019) pairing LED (light-emitting diode) light with a needle-stamped solution listing sh-Polypeptide-71; it shows how the ingredient has been applied and measured.
-
#316 – AMA #63: A guide for hair loss: causes, treatments, transplants, and sex-specific considerations - Peter Attia
Reviews low-level laser therapy and platelet-rich plasma growth-factor treatment for pattern hair loss, the light-plus-growth-factor approach through which sh-Polypeptide-71 has been tested on the scalp.
Only four items are listed: no further blog post, lecture or article discussing sh-Polypeptide-71 or VIP for hair in substantial depth was found outside ingredient databases, brand marketing pages and forums, which are excluded. No relevant content was found from Rhonda Patrick, Life Extension Magazine or Lifespan.io; Chris Kresser discusses VIP only as a level to correct in a mold-illness treatment protocol (Kresser mold-illness article), not hair.
Grokipedia
-
Grokipedia has no sh-Polypeptide-71 article; this page on the parent molecule covers VIP receptors, vessel-widening effects, its very short blood half-life and drug development, but not cosmetic or hair use.
Examine
No Examine article on sh-Polypeptide-71 or vasoactive intestinal peptide exists.
ConsumerLab
No ConsumerLab article on sh-Polypeptide-71 or vasoactive intestinal peptide exists.
Systematic Reviews
No systematic reviews or meta-analyses for sh-Polypeptide-71 were found on PubMed as of November 9, 2026.
Mechanism of Action
sh-Polypeptide-71 is made in Escherichia coli bacteria from a copy of the human gene for VIP; its European Union ingredient record allows up to 170 amino acids (EU CosIng record). Mature VIP is a 28-amino-acid signaling peptide that acts through VPAC1 and VPAC2 receptors (cell-surface sensors that raise cyclic AMP, an internal “on” signal), and also through PAC1 receptors (a related sensor) on some immune cells (review: Delgado 2013). Proposed hair-relevant actions:
- Vessel widening: VIP delivered into human skin increases local blood flow, partly through nitric oxide (a vessel-relaxing gas) and histamine H1 receptors (the receptors behind allergy-type vessel widening) (Wilkins 2004).
- Immune shielding: human scalp follicles carry VPAC1 and VPAC2 (Bertolini 2016); VIP protected cultured follicles from immune privilege loss induced by interferon-gamma (an immune alarm signal), but did not fully restore it once lost (Bertolini 2016).
Pharmacological properties:
- Half-life and distribution: given intravenously, VIP disappeared with a half-time of about 1 minute (Domschke 1978) and a distribution volume of about 14 ml/kg (Domschke 1978).
- Metabolism: it is broken down by peptidases (protein-cutting enzymes); no cytochrome P450 (the liver’s main drug-processing enzymes) pathway is described (review: Delgado 2013).
- Skin entry: molecules above about 500 daltons do not cross intact skin (review: Bos 2000); VIP is several times larger, so human hair studies used microneedling or laser-assisted delivery.
Historical Context & Evolution
VIP was isolated from intestine in 1970 as a peptide with broad effects on blood vessels, blood pressure, breathing and blood sugar (Said 1970). Its original uses were physiology research and later drug development: intravenous synthetic VIP (aviptadil) was tested in COVID-19 respiratory failure, where a trial with sponsor-affiliated authors reported no significant primary-endpoint (main outcome) benefit (Youssef 2022) and the National Institutes of Health TESICO trial stopped for futility (benefit judged unlikely) (Brown 2023).
Interest in hair grew from follicle biology. Mouse studies showed that peptide-carrying nerve fibers, including those marked for VIP, increase in number around follicles during anagen (the active growth phase) (Peters 2001). Human follicle work then identified VIP as a candidate guardian of follicle immune privilege, relevant to alopecia areata (an autoimmune disease causing patchy hair loss) (Bertolini 2016); a later review proposed VIP-like drugs to restore that protection (Bertolini 2020).
In cosmetics, the ingredient’s INCI (International Nomenclature of Cosmetic Ingredients) name marks it as a “sh-“ (synthetic human) peptide (EU CosIng record), and it was renamed from sh-Polypeptide-65 to sh-Polypeptide-71 (ci.guide entry). A 2017-priority patent combined it with sh-Oligopeptide-1 and sh-Polypeptide-7 as a multi-factor hair formulation (US Patent 10894074). From 2021, Gentile’s group reported case series using a solution containing it in pattern hair loss (Gentile 2021), post-COVID-19 shedding (Gentile 2022) and finasteride users (Gentile 2022). No trial has since tested the ingredient on its own, so its current standing rests on cell, organ-culture and combination-product data rather than any settled verdict.
Expected Benefits
High 🟩 🟩 🟩
No benefit reaches High: the hair-outcome data from two independent groups, case series and one small randomized trial, tested sh-Polypeptide-71 only inside multi-ingredient products, which makes them indirect evidence.
Medium 🟩 🟩
No benefit reaches Medium: the only human hair data tested sh-Polypeptide-71 inside multi-ingredient products delivered by microneedling or laser, which makes them indirect evidence regardless of design.
Low 🟩
Increased Scalp Hair Density
One group needled a multi-peptide solution listing sh-Polypeptide-71 into scalps with pattern hair loss (Gentile 2021), post-COVID-19 shedding (Gentile 2022) or a finasteride plateau (Gentile 2022). Another group’s randomized pilot trial laser-delivered a multi-peptide serum using maker-funded products (Nguyen 2026). Evidence is indirect: never tested alone.
Magnitude: Over 16 weeks, density rose 12 ± 2 hairs/cm² (± gives the spread around the average) in treated scalp while an untreated area of the same patients fell 1.1 hairs/cm² (p < 0.0001 between areas; p is the probability the difference arose by chance; not randomized) (Gentile 2021). After COVID-19, density rose 11 ± 2 hairs/cm² at 20 weeks while the untreated area fell 4.3 hairs/cm² (p < 0.0001 between areas; p = 0.069 versus baseline; not randomized) (Gentile 2022). In finasteride users, it rose 19 ± 2 hairs/cm² with no decrease in the untreated area (p < 0.0001 between areas; p = 0.0822 versus baseline, which the authors call significant; not randomized) (Gentile 2022). In the randomized trial (30 participants; products funded by the serum maker; two authors received lecture fees from the laser maker), density at 6 months was 22.3 ± 10.3% above baseline with laser plus KeraFactor serum versus 7.0 ± 10.5% with laser and light alone (p < 0.05 between groups) (Nguyen 2026); the maker lists sh-Polypeptide-71 among the line’s active ingredients (KeraFactor ingredient page).
Increased Hair Shaft Thickness ⚠️ Conflicted
A randomized pilot trial of laser-delivered KeraFactor serum, a line listing sh-Polypeptide-71, thickened hair shafts more than laser and light alone (Nguyen 2026). A finasteride-user case series found no significant change (Gentile 2022). Evidence is indirect: never tested alone. On balance, the controlled trial favors a modest gain.
Magnitude: At 6 months, hair shaft thickness was 11.9 ± 18.0% above baseline with laser plus serum and 13.8 ± 26.1% with laser, serum and light, versus -0.7 ± 12.8% with laser and light alone (p < 0.05 for each serum group versus laser and light alone; products funded by the serum maker) (Nguyen 2026).
Speculative 🟨
Protection Against Alopecia Areata Attack
VIP shielded cultured human scalp follicles from interferon-gamma induced loss of immune privilege (Bertolini 2016), and VIP receptors were reduced in alopecia areata lesions (Bertolini 2016). The basis is organ culture only.
Improved Scalp Microcirculation
VIP infused into human skin by microdialysis (a fine probe) raised blood flow (Wilkins 2004). Skin blood flow does not validly predict hair growth; no scalp study exists, so the basis is mechanistic.
Benefit-Modifying Factors
- Genetic polymorphisms: No study links VPAC1, VPAC2 or androgen-receptor gene variants to response; pattern hair loss is driven by inherited androgen sensitivity that sh-Polypeptide-71 is not proposed to block.
- Baseline hair status: One series enrolled only mild-to-moderate loss (Norwood–Hamilton I–III, Ludwig I–II, standard male and female pattern-loss grades) (Gentile 2021); the finasteride series included stages II–VI (Gentile 2022).
- Prior finasteride response: That series enrolled people whose regrowth on finasteride had stalled or been poor (Gentile 2022); data on people using no other hair-loss treatment are limited.
- Sex: Men and women were treated together; men reported higher satisfaction than women (Gentile 2022), and no sex-specific density analysis was reported.
- Pre-existing conditions: In alopecia areata, follicle VIP receptor levels are reduced in lesions (Bertolini 2016), which could blunt any effect; telogen effluvium (diffuse shedding after illness) often recovers on its own (systematic review: Hussain 2022), confounding uncontrolled results.
- Age: The COVID-19 series spanned ages 23–68 (Gentile 2022) without age-stratified results; more miniaturized follicles (shrunken follicles producing finer hairs) at older ages may respond less to any growth stimulus.
Potential Risks & Side Effects
High 🟥 🟥 🟥
No risk reaches High: no trial has recorded adverse events of sh-Polypeptide-71 itself, and the case series behind the hair data report no adverse-event counts.
Medium 🟥 🟥
No risk reaches Medium: human harm data come from microneedling of other products, from intravenous VIP and from one small laser-delivery trial of a multi-ingredient serum, all differing from sh-Polypeptide-71 alone in compound or route.
Low 🟥
Microneedling-Related Scalp Irritation
Most human hair data delivered sh-Polypeptide-71 by microneedling, which carries its own procedure risks. A systematic review of microneedling for hair loss found transient pain, scalp irritation and mild redness most common, and no serious adverse events (English 2022). Evidence is indirect: none of these studies isolated sh-Polypeptide-71.
Magnitude: No serious adverse events among 657 microneedling recipients in a review of 22 studies; the review gives no pooled comparison-group rate (English 2022).
Granulomatous or Allergic Reactions to Needled Products
Needling cosmetic serums into skin can trap them in the dermis (deeper skin layer) and trigger granulomas (firm inflammatory nodules) or body-wide hypersensitivity (Soltani-Arabshahi 2014); three such cases followed facial microneedling with other serums (Soltani-Arabshahi 2014). Evidence is indirect (different products).
Magnitude: Not quantified in available studies. Only case reports exist, and no study of sh-Polypeptide-71 products has counted such reactions.
Flushing, Low Blood Pressure and Diarrhea From Systemic Exposure ⚠️ Conflicted
Intravenous VIP caused flushing and a faster pulse (Domschke 1978). Infusions lowered blood pressure in one aviptadil trial (Brown 2023), but another found hypotension rates similar to placebo, with more diarrhea (Youssef 2022). Evidence is indirect: scalp absorption is unmeasured. On balance, infusions briefly lower pressure without clear excess hypotension.
Magnitude: Mean arterial pressure (the average pressure across a heartbeat) was 5–7 mmHg lower with aviptadil than with placebo during infusion days 2 and 3, returning to parity by 2 hours after each infusion (Brown 2023); in the second trial, hypotension occurred in 26.0% with aviptadil versus 21.5% with placebo (p = 0.6) (Youssef 2022) and diarrhea in 32.8% versus 1.5% (Youssef 2022).
Speculative 🟨
No risk is graded Speculative: no laboratory or animal study with an accessible abstract or full text reports a VIP harm at the scalp, so no laboratory finding could be graded.
Risk-Modifying Factors
- Genetic polymorphisms: No gene variant is known to alter VIP breakdown or receptor-mediated side effects; keloid-prone (raised, overgrown scars) genetic backgrounds raise scarring risk from repeated needling.
- Baseline blood pressure: People with low resting blood pressure would be most affected if meaningful VIP reached the circulation, given the pressure drop seen with intravenous aviptadil (Brown 2023).
- Sex: No sex difference in adverse events is reported; pregnancy and breastfeeding lack any safety data for this ingredient.
- Pre-existing conditions: Scalp psoriasis, eczema, infection, bleeding disorders and past hypersensitivity to needled products increase the chance of microneedling complications; allergic granulomas after needled serums occurred in patch-test-positive patients (Soltani-Arabshahi 2014).
- Age: Older adults more often take anticoagulants (blood thinners, such as warfarin or apixaban) and have thinner, slower-healing skin, which raises bruising and irritation risk from needling; no age-specific data exist.
Key Interactions & Contraindications
Documented interactions:
- None identified
Theoretical interactions (inferred from mechanism, not studied in humans):
- Topical minoxidil: Applied to freshly needled scalp, it may cause more stinging and greater absorption (lightheadedness); inferred from needle channels bypassing the skin barrier. Separating minoxidil from needling sessions by 24 hours is common practice.
- Blood pressure–lowering drugs (amlodipine, lisinopril, oral minoxidil) and PDE5 inhibitors (vessel-relaxing drugs that block phosphodiesterase type 5, such as tadalafil): Additive vessel widening could lower blood pressure if VIP is absorbed; inferred from intravenous VIP effects. Checking blood pressure after early sessions mitigates this.
- Anticoagulants (blood thinners: warfarin, apixaban) and antiplatelet drugs (clot-preventing drugs: clopidogrel): Prolonged pinpoint bleeding and bruising from microneedling; inferred from needle trauma. Shallower needle depth and firm pressure afterward reduce bleeding.
- Over-the-counter NSAIDs (non-steroidal anti-inflammatory drugs: aspirin, ibuprofen, naproxen): More bleeding and bruising at needle sites through reduced platelet function. Avoiding doses on needling days is common practice.
- Over-the-counter scalp irritants (adapalene, salicylic acid shampoos): Increased irritation, since needling has already breached the skin barrier. Pausing them for 24–48 hours around sessions is common practice.
- Bleeding-related supplements (fish oil, Ginkgo biloba, high-dose vitamin E): More bleeding at needle sites through reduced platelet clumping. Pausing them before sessions mitigates this.
- Nitric-oxide-raising supplements (L-arginine, L-citrulline, beetroot nitrate): Additive vessel widening, since VIP dilation is partly nitric-oxide dependent; possible lightheadedness if VIP is absorbed. Monitoring for dizziness mitigates this.
- Other scalp procedures (platelet-rich plasma, laser or light devices, other peptide serums): Cumulative skin injury from stacked procedures increases irritation and makes any regrowth impossible to attribute. Spacing procedures apart mitigates both.
Populations who should avoid sh-Polypeptide-71:
- People with previous granulomatous or allergic reactions to products needled into skin (Soltani-Arabshahi 2014)
- People with active scalp infection, open wounds or flaring psoriasis or eczema at the application site (needle-assisted use; inferred from needle trauma, no human data)
- People with bleeding disorders or on full anticoagulation (needle-assisted use; inferred from needle trauma, no human data)
- People prone to keloids (inferred from repeated skin injury, no human data)
- Pregnant or breastfeeding people (inferred from possible absorption of a vessel-widening peptide through needle channels, no human data; the EU record lists no SCCS (Scientific Committee on Consumer Safety) opinion (EU CosIng record))
- People with symptomatic low blood pressure (inferred from the pressure drop with intravenous aviptadil (Brown 2023); no topical data)
- People allergic to any product ingredient, such as polysorbates (needling carries allergens into the dermis; patch-test-positive patients developed granulomas after needled serums (Soltani-Arabshahi 2014))
Risk Mitigation Strategies
Doses and timings below follow common practice unless cited.
- Sterile solution for needling: Using only solutions supplied sterile for needle use mitigates infection and granuloma risk; the studied solution was sterile-filtered at 0.22 µm (Gentile 2022).
- Moderate needle depth: Hair studies in a systematic review used 0.5–2.5 mm needles (English 2022); staying near the shallow end limits bleeding, pain and scalp irritation.
- Patch test before needling: Applying the product to a small needled area and waiting 48–72 hours screens for allergic or granulomatous reactions before full-scalp use.
- Single-user, cleaned device: Personal stamps cleaned after each session and replaced per manufacturer schedule prevent infection and skin injury from blunted needles.
- Separation from other topicals: Waiting 24 hours after needling before minoxidil, retinoids (vitamin A–derived skin drugs) or acid shampoos reduces irritation and unintended absorption.
- Blood pressure check: Measuring blood pressure and pulse after the first sessions identifies the rare person with flushing or lightheadedness from systemic absorption.
- Lesion surveillance: New firm nodules or persistent redness at needle sites prompt stopping the product and dermatology review to address possible granulomas.
Therapeutic Protocol
Timing, cycling, titration and other parameters below reflect common practice unless cited.
- Studied regimen (microneedling-assisted): A vial of HR3 Matrix Hair Solution Alpha stamped into the scalp with a light-emitting device (Hairgen Booster), twice weekly for 16 weeks (Gentile 2021) or 20 weeks (Gentile 2022).
- Studied regimen (laser-assisted): Three 1927 nm thulium laser sessions 6 weeks apart, each followed by in-office KeraFactor serum, plus a daily home scalp solution and shampoo (Nguyen 2026); one arm added red light.
- Concentration: No published hair study reports an sh-Polypeptide-71 concentration, and retail labels list ingredients without amounts; dose cannot be expressed in milligrams.
- Leave-on serums and shampoos (marketed alternative): Used as directed by manufacturers without published regimens; molecules above about 500 daltons do not cross intact skin (review: Bos 2000), so penetration of a peptide this size is unlikely.
- Practitioners and origins: The needling-plus-light approach was published by Pietro Gentile (Tor Vergata University, Rome) with Korean hair clinics; the multi-peptide formula concept was patented by Skinqri (US Patent 10894074).
- Time of day: No data; evening sessions are common so the scalp is not exposed to sweat, sun or styling products for several hours.
- Half-life: Circulating VIP clears with a half-time of about 1 minute (Domschke 1978); how long it persists in scalp tissue after needling is unknown.
- Single versus split dosing: Each session uses one application; splitting doses has not been studied, and needling more than twice weekly was not tested.
- Genetic polymorphisms: No pharmacogenetic variant is known to change dose or response.
- Sex: Men and women used the same regimen; no sex-specific dosing exists (Gentile 2022).
- Age: Adults aged 23–68 used the same regimen (Gentile 2022); slower skin healing at older ages may favor shallower needles.
- Baseline biomarker: A baseline phototrichogram (magnified photo-based hair count) sets starting density; the pattern-loss (Gentile 2021) and COVID-19 (Gentile 2022) series enrolled only Norwood–Hamilton I–III and Ludwig I–II, so advanced-stage response is uncertain.
- Pre-existing conditions: The pattern-loss series excluded scalp infections, eczema, psoriasis, poor wound healing and autoimmune disease (Gentile 2021); response in these groups is unknown.
Discontinuation & Cycling
- Duration: Published use lasted 16–20 weeks; whether the regimen is meant to be short-term or continued indefinitely is undefined, and no follow-up after stopping was reported.
- Withdrawal effects: None known; no rebound shedding has been described after stopping, though no study looked.
- Tapering: Not applicable; no tapering protocol exists, and stopping abruptly carries no known risk.
- Cycling: No evidence supports or argues against cycling; no study has examined maintenance, cycling or what happens to gained hair after stopping.
Sourcing and Quality
- Ingredient identity: Labels list it under its INCI name “sh-Polypeptide-71” (EU CosIng record); similar names such as Oligopeptide-71 and sh-Oligopeptide-71 are separate INCI entries for different substances.
- Production and purity: It is a recombinant protein made in Escherichia coli (EU CosIng record); purity, endotoxin (bacterial residue) content and activity are rarely disclosed by brands.
- Concentration and stability: Concentrations are not published, and VIP is quickly degraded by peptidases (review: Delgado 2013); airtight, refrigerated or encapsulated formulations are designed to limit breakdown.
- Third-party testing: No independent laboratory tests sh-Polypeptide-71 products; ConsumerLab and Examine have no coverage.
- Products containing it: HR3 Matrix Hair Solution Alpha was the studied solution (Gentile 2021); retail listings include Kera Factor Lash Serum and Blueprint Peptide Shampoo (Skinsort ingredient listing), without ingredient-specific efficacy data.
Practical Considerations
- Time to effect: Density changes were measured at 16 weeks (Gentile 2021) or 20 weeks (Gentile 2022) of twice-weekly needling sessions; the laser trial measured hair density 1 and 6 months after treatment (Nguyen 2026).
- Common pitfalls: Assuming a rinse-off shampoo delivers a large peptide into follicles; attributing regrowth to sh-Polypeptide-71 when products combine many actives; and judging results without baseline photographs or hair counts.
- Regulatory status (EU): It is a listed cosmetic ingredient with hair- and skin-conditioning functions and no restrictions or safety-committee opinion (EU CosIng record).
- Regulatory status (US): Any over-the-counter product promoted for external use as a hair grower or for hair-loss prevention is regarded as a new drug requiring an approved application (21 CFR 310.527).
- Cost and access: Products are widely sold online as cosmetics and are not exceptionally expensive or hard to obtain; the studied needling kit requires repeated purchases over months.
Interaction with Foundational Habits
- Sleep: None known. No study links sh-Polypeptide-71 to sleep; evening sessions avoid daytime sweat and sun on freshly needled skin.
- Nutrition: Indirect. No nutrient interaction is described, but adequate protein, iron and calorie intake support hair growth generally; nitric-oxide-raising foods such as beetroot could add to vessel widening if VIP is absorbed.
- Exercise: Indirect. No direct interaction; heavy sweating on freshly needled skin may raise irritation and infection risk, so sessions after, rather than before, workouts are common practice.
- Stress management: Indirect, potentiating in theory. Peptide-carrying nerves around follicles remodel through the hair cycle (Peters 2001), linking nervous-system signaling to hair growth; stress reduction may support the same pathway, but no study tested the combination.
Monitoring Protocol & Defining Success
Before starting, a baseline assessment records hair density in a marked target area by phototrichogram, standardized global scalp photographs under fixed lighting and camera distance, and the hair-loss stage. People with alopecia areata add a SALT (Severity of Alopecia Tool, percent scalp hair loss) score, and anyone with low or variable blood pressure records a resting blood pressure and pulse. Ongoing monitoring repeats blood pressure after the first two sessions if flushing or lightheadedness occurs, then repeats the phototrichogram and photographs at 8 weeks, 16–20 weeks (the timepoints used in published series), and every 6 months thereafter if use continues. Success is defined as a sustained density gain in the target area over the individual’s own baseline, ideally exceeding change in an untreated comparison area; absence of change by 20 weeks suggests a non-response.
| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|---|---|---|---|
| Hair density (phototrichogram, hairs/cm²) | No established target; track change from own baseline | Expected to change | Same marked area and magnification each time; an untreated comparison area helps separate effect from natural variation (Gentile 2021) |
| SALT score (alopecia areata only) | No established target; track change from own baseline | Expected to change (speculative) | Scores percent scalp hair loss from 0 to 100; relevant only if used for alopecia areata |
| Blood pressure and pulse | Pulse 60–100 beats per minute (standard reference range); blood pressure: no established target, compare with own pre-treatment reading | Safety check | Seated after 5 minutes rest; intravenous VIP lowered pressure (Brown 2023) and raised pulse (Domschke 1978) |
Qualitative markers:
- Visible scalp coverage in standardized photographs
- Shedding during washing or brushing
- Hair shaft feel and thickness
- Scalp comfort, redness or nodules after sessions
Emerging Research
- No single-ingredient trial: Registered and published hair trials test only multi-ingredient products listing sh-Polypeptide-71; a trial isolating the ingredient would show whether it adds anything beyond the delivery method and the other actives.
- Peptide serum versus minoxidil (NCT07536100): A triple-masked (participants, clinicians and assessors blinded) randomized trial in 80 adults with pattern hair loss compares a peptide serum with 2% minoxidil on density at 12 and 24 weeks. Composition is undisclosed; a positive result would support the peptide-serum category, a null result would weaken it.
- Thulium laser with growth factor serum (NCT07079657): Registered completion (October 2025) has passed; the record still lists recruiting with no posted results, but the 30-person Hamburg trial is published: KeraFactor serum plus laser raised density more than laser and light alone (Nguyen 2026). Products were maker-funded; no arm isolated sh-Polypeptide-71.
- KeraFactor solution versus placebo (NCT07810504): A double-masked randomized trial, with the serum maker as collaborator, assigns 40 women with pattern hair loss to KeraFactor solution, red-light cap, both, or placebo; density is measured at 6 months (completion due January 2027). A positive result would strengthen the product-line evidence, a null result would weaken it.
- VIP-like drugs for alopecia areata: A review proposes VIP analogs such as aviptadil to restore follicle immune privilege (Bertolini 2020); clinical testing would show whether this mechanism matters in people.
- Microneedling trials: The microneedling systematic review calls for large randomized trials of microneedling alone and as an add-on, which would clarify how much of the reported regrowth needling explains (English 2022).
Conclusion
sh-Polypeptide-71 is a lab-made copy of a nerve-released signaling peptide sold as a cosmetic ingredient in scalp serums, shampoos and lash products. Its appeal for hair comes from work showing that the natural peptide widens small blood vessels in skin and, in donated scalp tissue, helps protect hair follicles from immune attack.
The human evidence is thin and indirect. A few small studies, mostly without random assignment, pressed the ingredient into the scalp with a needle stamp or delivered it by laser, always mixed with several other lab-made proteins and often with light therapy. Hair counts rose, including in one small randomized study, but no study separates this ingredient from the delivery method, the light or the other ingredients, and some gains could have arisen by chance.
Risks appear low but are poorly documented. The main concerns are the needling itself, rare inflammatory reactions when cosmetic serums are pushed into skin, and, in theory, flushing or lower blood pressure if enough peptide enters the bloodstream.
For adults willing to follow demanding hair routines, the ingredient remains an unproven add-on whose benefit, if any, is not yet separable from the methods used to deliver it. The products tested and a related patent are commercial: the maker paid for the products in the randomized study, two of its authors had fees from the laser maker, and an earlier trial of the natural peptide had authors tied to its sponsor.